| scholarly article | Q13442814 |
| P2093 | author name string | Yu Han | |
| Pengfei Li | |||
| Jianjun Chen | |||
| Qi Li | |||
| Peng Xie | |||
| Xinyu Zhou | |||
| Yiyun Liu | |||
| Peng Zheng | |||
| Haiyang Wang | |||
| Yuqing Zhang | |||
| Dezhi Zou | |||
| P2860 | cites work | Acute Effects of Ketamine on Memory Systems and Psychotic Symptoms in Healthy Volunteers | Q38425577 |
| Acute reduction in anxiety after deep transcranial magnetic stimulation (DTMS) in unipolar major depression- a systematic review and meta-analysis | Q38652199 | ||
| Ketamine for treatment-resistant depression: recent developments and clinical applications | Q38800172 | ||
| Divergent Urinary Metabolic Phenotypes between Major Depressive Disorder and Bipolar Disorder Identified by a Combined GC-MS and NMR Spectroscopic Metabonomic Approach | Q38985361 | ||
| Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: a meta-analysis of stimulus parameter effects | Q39377437 | ||
| Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression | Q40343665 | ||
| A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression | Q42688037 | ||
| Interpretation of random effects meta-analyses. | Q43810883 | ||
| A novel urinary metabolite signature for diagnosing major depressive disorder | Q43827823 | ||
| Acute ketamine-induced neuroplasticity: ribosomal protein S6 phosphorylation expression in drug addiction-related rat brain areas. | Q45824858 | ||
| Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls | Q46169249 | ||
| Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism | Q46565524 | ||
| Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder | Q47591336 | ||
| Should ketamine be used for the clinical treatment of depression? | Q47632993 | ||
| Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study | Q47637552 | ||
| Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression | Q47852326 | ||
| Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder | Q47930906 | ||
| Heartbeat evoked potentials mirror altered body perception in depressed patients. | Q48690473 | ||
| Neuroplasticity and the next wave of antidepressant strategies | Q21129480 | ||
| Grand challenges in global mental health | Q22251122 | ||
| Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication | Q22253031 | ||
| A rating scale for depression | Q24564540 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
| Antidepressant effects of ketamine in depressed patients | Q29617327 | ||
| A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 | ||
| mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists | Q29618120 | ||
| Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis | Q29619093 | ||
| NMDAR inhibition-independent antidepressant actions of ketamine metabolites. | Q30370600 | ||
| The potential biomarker panels for identification of Major Depressive Disorder (MDD) patients with and without early life stress (ELS) by metabonomic analysis | Q33679513 | ||
| A randomized controlled trial of intranasal ketamine in major depressive disorder | Q34288196 | ||
| The role of ketamine in treatment-resistant depression: a systematic review | Q34449588 | ||
| Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression | Q34653606 | ||
| Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial | Q34655680 | ||
| Sex-specific urinary biomarkers for diagnosing bipolar disorder | Q34757521 | ||
| Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial | Q35200000 | ||
| Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry | Q35580090 | ||
| Remission versus response: the new gold standard of antidepressant care. | Q35717226 | ||
| Urinary metabolite markers of precocious puberty | Q35722258 | ||
| Identification and validation of urinary metabolite biomarkers for major depressive disorder | Q36508139 | ||
| Report by the ACNP Task Force on response and remission in major depressive disorder | Q36516394 | ||
| Impact comparison of ketamine and sodium thiopental on anesthesia during electroconvulsive therapy in major depression patients with drug-resistant; a double-blind randomized clinical trial | Q36939533 | ||
| Abnormalities in white matter microstructure associated with chronic ketamine use. | Q37409619 | ||
| Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories | Q37424333 | ||
| Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. | Q37733240 | ||
| Left versus right repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomised controlled trials | Q38151375 | ||
| Bilateral vs. unilateral repetitive transcranial magnetic stimulation in treating major depression: a meta-analysis of randomized controlled trials | Q38217010 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | major depressive disorder | Q42844 |
| placebo | Q269829 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 2859-2867 | |
| P577 | publication date | 2016-11-03 | |
| P1433 | published in | Neuropsychiatric Disease and Treatment | Q15716332 |
| P1476 | title | Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies | |
| P478 | volume | 12 |
| Q58763117 | Characteristics of patients expressing an interest in ketamine treatment: results of an online survey |
| Q57174889 | Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review |
| Q90146293 | Exploring patients' and carers' views about the clinical use of ketamine to inform policy and practical decisions: mixed-methods study |
| Q58545289 | Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial |
| Q57164566 | Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study |
| Q93084000 | Keeping up with the clinical advances: depression |
| Q55474333 | NMDA antagonists for treating the non-motor symptoms in Parkinson's disease. |
| Q33871737 | Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression? |
| Q47651782 | New medications for treatment-resistant depression: a brief review of recent developments |
| Q97882890 | Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study |
| Q47303882 | The medial habenula and interpeduncular nucleus circuitry is critical in addiction, anxiety, and mood regulation. |
| Q92898347 | Treatment for Substance Use Disorder With Co-Occurring Mental Illness |
| Q47594738 | Use of Ketamine in Elderly Patients with Treatment-Resistant Depression |
Search more.